Biotechnology / Medical Research

Spectrum Pharmaceuticals appoints Joseph Turgeon as president and chief operating officer - Form 8-K

Spectrum Pharmaceuticals Inc:Effective April 17, company appointed Joseph Turgeon as president and chief operating officer.On April 17, Ken Keller resigned from his position as executive vice president and chief operating officer.Keller will continue to be employed by company through April 28 in...

5:03pm EDT

Karyopharm Therapeutics Inc announces auditor change - Form 8-K

Karyopharm Therapeutics Inc:Says on April 11, it selected Ernst & Young LLP (E&Y) as independent registered public accounting firm.Dismisses McGladrey LLP from service as independent registered public accounting firm.Engages E&Y on April 17.

4:06pm EDT

GlaxoSmithKline Plc and Genmab A/S receive FDA approval for Arzerra(r) (ofatumumab) as first-line treatment in combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia

GlaxoSmithKline Plc and Genmab A/S:U.S. Food and Drug Administration (FDA) has approved Supplemental Biologic License Application (sBLA) for use of Arzerra(r) (ofatumumab), a CD20-directed monoclonal antibody, in combination with chlorambucil for treatment of previously untreated patients with...

3:52pm EDT

CEL-SCI Corp announces closing of public offering for gross proceeds of $10 mln

CEL-SCI Corp:Closes underwritten public offering of units consisting of aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock.Units sold at $1.40 per unit and resulted in aggregate gross proceeds of about $10 mln.Intends to use the...

11:55am EDT

Actelion Ltd gives FY 2014 and FY 2015 core earnings outlook

Actelion Ltd:Expects core earnings (core operating income) growth in low-single digit range for FY 2014.Expects FY 2015 core earnings to grow in single-digit percentage range.FY 2013 core earnings of 619 million Swiss francs.

Wednesday, 16 Apr 2014 08:00pm EDT

Welichem Biotech Inc responds to filing of take-over bid circular

Welichem Biotech Inc:Says that it has become aware, through filing on SEDAR on April 15, 2014 of take-over bid circular dated April 11, that LJ Resources Co., Ltd, is making an unsolicited formal offer to purchase all of outstanding common shares of the company at price of $0.15 per common...

Wednesday, 16 Apr 2014 07:01pm EDT

Vital Therapies Inc prices initial public offering

Vital Therapies Inc:Prices initial public offering of 4,500,000 shares of common stock at price to public of $12 per share.Shares will begin trading on NASDAQ Global Market on April 17 under ticker symbol 'VTL.Grants underwriters 30-day option to purchase up to additional 675,000 shares of common...

Wednesday, 16 Apr 2014 05:46pm EDT

Islet Sciences Inc announces positive 12-Week phase 2 clinical results for SGLT2 Inhibitor Remogliflozin Etabonate

Islet Sciences Inc:Positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics.Primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability.Remogliflozin etabonate is selective SGLT2...

Wednesday, 16 Apr 2014 12:16pm EDT

Cleveland BioLabs Inc completion of Phase 1 Study of CBL0102

Cleveland BioLabs Inc:Achievement of all objectives in Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule.Study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies.Patients had...

Wednesday, 16 Apr 2014 08:00am EDT

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.